Prognostic value of estrogen and prolactin receptor analysis in human breast cancer. 1985

N Waseda, and Y Kato, and H Imura, and M Kurata

Hormone receptors for estrogen (ER), progesterone (PGR) and prolactin (PRL-R) were measured in primary breast cancer tissues obtained from 214 patients at radical mastectomy. The patients were followed up at intervals of one to three months to examine the relationship between hormone receptor status and prognosis. ER status was related to PGR status but not to PRL-R status. PRL-R was more frequently detectable in pathologic stage 3 than in stage 1 & 2 (22% vs. 10%, P less than 0.05) whereas ER and PGR were not different between stage 1 & 2 and stage 3 groups. The influence of receptor status on prognosis was analyzed in 164 patients of stage 1 & 2 by means of the actuarial life table technique. The recurrence-free interval was not related to ER, PGR or PRL-R status. The ER-positive group was associated with significantly prolonged survival compared with that of ER-negative patients at 42 to 51 months after surgery. PRL-R positive patients had a significantly worse survival than the PRL-R negative group (P less than 0.05). These findings indicate that receptor status may provide useful prognostic information in patients with early breast cancer and that the lactogenic hormone may play an unfavorable role in relation to the prognosis of human breast cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D011981 Receptors, Prolactin Labile proteins on or in prolactin-sensitive cells that bind prolactin initiating the cells' physiological response to that hormone. Mammary casein synthesis is one of the responses. The receptors are also found in placenta, liver, testes, kidneys, ovaries, and other organs and bind and respond to certain other hormones and their analogs and antagonists. This receptor is related to the growth hormone receptor. Prolactin Receptors,PRL Receptors,Prolactin Receptor,Receptors, PRL,Receptor, Prolactin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females

Related Publications

N Waseda, and Y Kato, and H Imura, and M Kurata
November 1978, Cancer research,
N Waseda, and Y Kato, and H Imura, and M Kurata
January 2014, International journal of clinical and experimental medicine,
N Waseda, and Y Kato, and H Imura, and M Kurata
April 2017, Current oncology (Toronto, Ont.),
N Waseda, and Y Kato, and H Imura, and M Kurata
February 2003, Pathology international,
N Waseda, and Y Kato, and H Imura, and M Kurata
October 1974, Surgery, gynecology & obstetrics,
N Waseda, and Y Kato, and H Imura, and M Kurata
August 1979, Cancer,
N Waseda, and Y Kato, and H Imura, and M Kurata
August 1986, Cancer research,
Copied contents to your clipboard!